ACTL6A

Across TCGA pan-cancer cohorts, ACTL6A RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ACTL6A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ACTL6A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACTL6A is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, BLCA, and LUAD are the cancer types where ACTL6A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACTL6A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.888	<.001	12	view →
BLCA	Male	III,IV	+1.604	<.001	11	view →
LUAD	Male	III,IV	+1.194	<.001	11	view →
COAD	Female	II,III,IV	+1.190	<.001	11	view →
LUSC	Female	All	+2.200	<.001	9	view →
LIHC	Male	II,III,IV	+1.247	<.001	9	view →
STAD	Male	II,III,IV	+1.108	<.001	8	view →
READ	All	All	+0.647	.002	7	view →
UCEC	All	II,III,IV	+0.957	.002	6	view →
BRCA	All	II,III,IV	+0.948	<.001	6	view →
KIRP	All	II,III,IV	+0.555	.004	6	view →
CHOL	Male	All	+2.875	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ACTL6A–HNSC

Open the HNSC breakdown →